AI assistant
TALPHERA, INC. — Director's Dealing 2019
Feb 13, 2019
35181_dirs_2019-02-13_6c6d37be-eea3-4ca1-bd93-6b7664428c96.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2019-02-11
Reporting Person: ASADORIAN RAFFI (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-02-11 | Common Stock | A | 68750 | $0.00 | Acquired | 120750 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-02-11 | Stock Option (Right to Buy) | $2.51 | A | 137500 | Acquired | 2029-02-11 | Common Stock (137500) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: The restricted stock units shall vest in three equal consecutive annual installments on February 11, 2020, February 11, 2021 and February 11, 2022.
F3: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months.